智通财经APP讯，心玮医疗-B(06609)发布公告，于2025年12月30日，该公司斥资214.52万港元回购4万 股。 （原标题：心玮医疗-B(06609)12月30日斥资214.52万港元回购4万股） ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | H股 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

Shanghai HeartCare Medical Technology Corporation Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 上海，2025年12月29日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生。 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 茲提述上海心瑋醫療科技股份有限公司（「本公司」）日期為2025年12月12日的公 告，內容有關（其中包括）建議根據將尋求本公司股東批准的特別授權發行內 資股及建議修訂本公司組織章程細則。 本公司董事會謹此宣佈，本公司擬於2026年1月16日（星期五）召開臨時股東大 會（「臨時股東大會」）及H股類別股東大會（「H股類別股東大會」）。為釐定有權 出席臨時股東大會及H股類別股東大會並於會上投票的本公司H股股東名單， 本公司將自2026年1月13日（星期二） ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

心玮医疗-B(06609)发布公告，于2025年12月29日斥资299.15万港元回购5.61万股。 ...

Group 1 - The company, Heartway Medical-B (06609.HK), announced a share buyback plan on December 29, 2025, involving an expenditure of HKD 2.99 million to repurchase 56,000 shares [1] - The buyback price per share is set between HKD 52.5 and HKD 53.75 [1]

Core Viewpoint - Heartway Medical-B (06609) announced a share buyback plan, intending to repurchase 56,100 shares for a total cost of HKD 2.9915 million by December 29, 2025 [1] Group 1 - The company plans to spend HKD 2.9915 million on the buyback [1] - The total number of shares to be repurchased is 56,100 [1] - The buyback is scheduled to be completed by December 29, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 ...

Core Viewpoint - The stock of Xinwei Medical-B (6609.HK) surged over 12%, reaching a peak of 54.05 HKD, driven by positive market sentiment regarding brain-computer interface (BCI) technology and its commercial potential in a nearly 10 billion USD market [1]. Industry Summary - The brain-computer interface sector is at a critical stage characterized by increased policy support, rapid technological advancements, and accelerated commercialization [1]. - The market for BCI technology is projected to be a nearly 10 billion USD blue ocean market, indicating significant growth opportunities [1]. Company Summary - Xinwei Medical is highlighted as a key player in the BCI space, benefiting from advancements in invasive, semi-invasive, and interventional technologies that offer unmatched advantages in signal quality and control precision [1]. - Domestic companies, including Xinwei Medical, have made technological breakthroughs in flexible electrodes and real-time Chinese language decoding, contributing to the acceleration of domestic substitution and showcasing significant long-term growth potential [1].

心玮医疗-B(6609.HK)大涨超12%，最高触及54.05港元。 本文源自：金融界AI电报 ...